The 60 Billion Vaccine Giant Signs a Big Order with Mexico to Purchase 35 Million Doses! The Market Starts Betting on Vaccines?

The World Bank stated that it will draw expertise and experience from the mass immunization program and other public health work it has participated in. UAE Minister of Health and Prevention Abdullahman Oves said that the research results show that the vaccine is safe and effective. The vaccinated subjects not only have antibodies against the new crown pneumonia virus, but also have no obvious side effects. The safety of the vaccine is guaranteed.
 

Near the end of the year, as the weather turns cooler, the new crown vaccine has once again become a hot spot!
 

Based on the Wall Street Journal and other media reports, Cansino, with a total market value of nearly 60 billion, ushered in a large order. The international phase III clinical trial of the recombinant new coronaavirus vaccine (Ad5-nCoV) developed by the team of Chen Wei, an academician of the Chinese Academy of Engineering and Cansino Biotech, has made progress in Mexico. At the same time, on Tuesday, local time, Mexico and Cansino Biotech signed a framework agreement to purchase 35 million doses of the new coronavirus vaccine from Cansino Biotech. Mexico also purchased 39 million doses and 17 million doses of COVID-19 vaccine from AstraZeneca and Pfizer respectively. CanSino Bio and Pfizer’s vaccines are expected to be available in December at the earliest, and AstraZeneca’s vaccines are expected to be available in March next year.
 

In addition, the latest news related to vaccines is that the World Bank has approved US$12 billion in financing to help developing countries purchase and distribute coronavirus vaccines, testing and treatment. Russian President Putin said, The Russian regulatory agency has registered a second new coronavirus vaccine developed by the Siberian Virus Research Institute for domestic use.
 

So, what is the market's attitude toward this? Some hedge fund managers who manage hundreds of billions of dollars said that the market expects that any COVID-19 vaccine approved this year will only be partially effective. If the effectiveness can reach 50% or 60%, it will revive some traditional industries.
 

Order from Mexico
 

According to the Wall Street Journal, on Tuesday, local time, Mexico signed an agreement with three companies to develop a vaccine against Covid-19, and is expected to ensure a dose for more than 100 million people by 2021. Mexico will purchase 39 million doses of the final vaccine from AstraZeneca PLC of the United Kingdom, Pfizer will purchase 17 million doses, and China's CanSino Biologics will purchase 35 million doses. The country also participates in the International Vaccine Alliance COVAX, which is expected to receive a dose of about 26 million people.
 

President Andres Manuel López Obrador said that he hopes Mexico can start providing vaccines to people in December or at the latest in the first quarter of next year. Mexican Foreign Minister Marcelo Ebrard said that Mexico will evaluate CanSino's ongoing Phase 3 clinical trial within a few days and is negotiating with pharmaceutical companies in the United States, Germany, Russia, France and Italy.
 

The cost of the final vaccine is estimated to be approximately US$1.7 billion. Mexico’s Finance Minister Arturo Herrera stated that Mexico has already paid $159 million in advance and will increase these advances to $321 million by the end of this year.
 

According to health officials, Mexico has a population of 126 million, one of the countries with the highest number of deaths among SARS-CoV-2 infections. As of Monday, the number of confirmed cases in Mexico is close to 84,000.
 

In a survey of 1,000 Mexicans conducted by Consulta Mitovsky, a mobile phone consulting company, from October 9 to 11, 34% said that if it is free or cheap, they will seek to be the first to be vaccinated. About half of the people said they wanted others to be the first, and 12% said they did not get vaccinated.
 

In fact, in September, another vaccine in China: an inactivated vaccine was approved for emergency use in the UAE.
 

 

World Bank'd Big Hand
 

It is reported that the World Bank has approved US$12 billion in financing to help developing countries purchase and distribute coronavirus vaccines, testing and treatment.
 

The World Bank said in a statement on Tuesday evening local time that the $12 billion 'envelope' is part of a wider package of up to $160 billion provided by the World Bank Group, which aims to help developing countries deal with COVID-19 pandemic.
 

The World Bank said its COVID-19 emergency response plan has covered 111 countries. Citizens of developing countries also need to obtain a safe and effective COVID-19 vaccine.
 

The president of the bank, David Malpass, said in a statement, 'We are expanding the fast-track approach to address the COVID emergency so that developing countries can obtain vaccines fairly and equally.' He also said, 'Access to safe and effective vaccines and enhanced delivery systems are the keys to changing the course of the pandemic and helping countries that have suffered catastrophic economic and financial impacts move towards recovery.'
 

The World Bank statement pointed out that the International Finance Corporation, the World Bank’s private sector lender, is investing in vaccine manufacturers through a $4 billion global health platform.
 

The development and deployment of vaccines are essential to help stop the outbreak of the coronavirus, which has killed more than 1 million people and sickened 38 million people, disrupted the economy and left millions of people unemployed.
 

The World Bank stated that it will draw expertise and experience from the mass immunization program and other public health work it has participated in. UAE Minister of Health and Prevention Abdullahman Ovis said that the research results show that the vaccine is safe and effective. The vaccinated subjects not only have antibodies against the new coronavirus pneumonia virus, but also have no obvious side effects, and the safety of the vaccine is guaranteed.
 

The Market Bets on Vaccine Effectiveness
 

Dmitry Balyasny, a world-renowned hedge fund manager, said in a virtual discussion at Citigroup this week that the market expects that any COVID-19 vaccine approved this year will only be partially effective. When vaccine injections are more effective, 50% to 60% effectiveness will make some stocks rebound.
 

Balyasny's company manages approximately $118 billion. He said that once the effect of the vaccine injection reaches 80% to 90%, the market will begin to pay attention to the current weakness of the companies that have been severely affected. Although he did not disclose any specific stocks and sectors, he said that this sentiment will push the stock market beyond the large technology sectors. During the epidemic, stocks in some traditional sectors, especially those in the retail and financial sectors, eclipsed the rise of large technology stocks such as Apple.
 

In fact, some recent trials of new coronavirus vaccines and drugs have encountered setbacks and have frustrated the coronavirus vaccine race. Johnson & Johnson stopped all doses related to the vaccine trial on Monday after participants developed an 'unexplainable disease'. After the independent expert committee raised safety issues, U.S. competitor Eli Lilly also suspended its COVID-19 antibody treatment trials. In September, the British pharmaceutical group AstraZeneca suspended its trial because of concerns that participants might have serious adverse reactions. Although the trial in the United Kingdom has resumed, the trial in the United States has been shelved and is undergoing further review by the U.S. Food and Drug Administration.
 

Judging from the current situation, let alone effectiveness, there may be only two U.S. vaccines that can be approved within this year. It is reported that US drugmakers need to apply to the UAE for a candidate coronavirus vaccine before the end of November in order to obtain a realistic opportunity for FDA authorization before the end of this year. At this point, there are only two candidate vaccines that can be completed within the prescribed deadline: Pfizer and BioNTech jointly produced BNT162b2 and Moderna mRNA-1273.
 

However, the CEO of Eli Lilly recently said in an interview with the media that even if there is a vaccine, Covid will "pop." According to him, vaccines alone are not enough, and medications are needed.